DiaCarta
DiaCarta Molecular Test for SARS-CoV-2, Variants Obtains CE Mark
The firm is also pursuing FDA Emergency Use Authorization for its SARS-CoV-2 variant detection test, which uses molecular clamping technology.
The firm has launched a validation trial for its in-development QuantiDNA cell-free DNA chemotherapy response assay in late-stage smoking-related cancers.
FDA Grants Emergency Use Authorization for DiaCarta Multiplex Coronavirus Test
The test is designed to detect the SARS-CoV-2 Orf1ab gene in upper respiratory specimens and sputum, according to the California-based company.
In Brief This Week: Thermo Fisher Scientific, BioReference Laboratories, PerkinElmer, and More
News items for the in vitro diagnostics industry for the week of July 13, 2020.
DiaCarta Gets FDA Emergency Use Authorization for Coronavirus PCR Test
The company said it has recently expanded its manufacturing capacity to 500,000 tests per week and is planning to increase it another fourfold.
Mar 23, 2020
DiaCarta SARS-CoV-2 Test Kit Receives CE Mark
Feb 12, 2018
DiaCarta Raises $45M in Series B Funding
Feb 21, 2017